Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
February 07, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Announces Pricing of Public Offering
January 04, 2024 22:45 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of...
Voyager Therapeutics Announces Proposed Public Offering
January 04, 2024 16:14 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has...
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
January 02, 2024 07:00 ET
|
Voyager Therapeutics, Inc.
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of...
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
December 06, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
November 06, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development...
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 30, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
September 25, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...